Cascade Financial Partners’s FibroBiologics FBLG Stock Holding History

Cascade Financial Partners’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.7K	Buy	16,428 +699	+4%	+$4.16K	﹤0.01%	263
2025 Q4	$70.7K	Buy	15,729 +825	+6%	+$5.81K	0.01%	269
2025 Q3	$163K	Buy	14,904 +375	+3%	+$4.49K	0.02%	258
2025 Q2	$181K	Buy	14,529 +1,525	+12%	+$27.5K	0.02%	256
2025 Q1	$234K	Sell	13,004 -1,126	-8%	-$32.2K	0.03%	219
2024 Q4	$565K	Sell	14,130 -1,000	-7%	-$53.7K	0.07%	132
2024 Q3	$871K	Sell	15,130 -623	-4%	-$41.4K	0.11%	105
2024 Q2	$1.57M	Buy	+15,753	New	+$3M	0.21%	73

Other funds holding FBLG

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cascade Financial Partners's FBLG Position: Q1 2026 in Review

Cascade Financial Partners increased its FibroBiologics (FBLG) stake by 4.4% in Q1 2026, buying an estimated $4.16K and bringing the position to 16,428 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #263.

Cascade Financial Partners first reported a position in FBLG in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.57M in Q2 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

Cascade Financial Partners held 16,428 shares of FibroBiologics worth $21.7K as of Q1 2026.
Cascade Financial Partners bought 699 FibroBiologics shares in Q1 2026, an estimated $4.16K.
FibroBiologics made up ﹤0.01% of Cascade Financial Partners's portfolio in Q1 2026, its #263 holding.
Cascade Financial Partners first reported a position in FibroBiologics in Q2 2024 and has held it in 8 quarters since.
Cascade Financial Partners's FibroBiologics position peaked at $1.57M in Q2 2024.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Cascade Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.